EUVIMEDEUVIMED entdecken
Open Access

Gefitinib Facilitates Bone Fracture Healing via Inhibition of the EGFR Pathway and Counteracting SOX9-driven Bone Metabolic Reprogramming

Ning Xu, Gongwu Yuan, Wenbo Zeng, Ximing Liu, M A Wan, Suyang Xu, Yikang Bi, Hai Hu, Yafeng Xu, Shenghui Lan

In Vivo · 2025

DOI: 10.21873/invivo.13942 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Ning Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Eighth People's Hospital, Jiangsu University, Shanghai, P.R. China. Hauptthemen laut MEDLINE: Gefitinib, SOX9 Transcription Factor, ErbB Receptors, Fracture Healing. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: To investigate the role of epidermal growth factor receptor (EGFR) inhibition in enhancing bone fracture healing by modulating box transcription factor 9 (SOX9) and bone metabolism. MATERIALS AND METHODS: A rat femoral fracture model was used. Techniques included histological analysis, X-ray scoring, micro-computed tomography, immunohistochemistry, and biomechanical testing. Serum markers were analyzed with enzyme-linked immunosorbent assay, while quantitative real-time polymerase chain reaction and western blotting assessed molecular pathways. Metabolic changes were measured using a Seahorse analyzer. An EGFR inhibitor, gefitinib, was used to examine its impact on periosteal stem cell differentiation and metabolism. RESULTS: EGFR inhibition improved bone callus formation and quality, increased cartilage callus, and upregulated bone formation markers. Gefitinib enhanced oxidative phosphorylation and fatty acid oxidation, counteracting negative effects from lipid-reduced serum on osteoblastic differentiation of periosteal stem cell. SOX9 overexpression reduced the benefits of EGFR inhibition. CONCLUSION: Gefitinib enhances bone fracture healing by modulating lipid metabolism through SOX9, suggesting its potential as a therapeutic agent for improving fracture outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GefitinibSOX9 Transcription FactorErbB ReceptorsFracture HealingSignal TransductionBone and BonesAnimalsRatsCell DifferentiationDisease Models, AnimalOsteogenesisMaleFractures, BoneLipid MetabolismFemoral FracturesX-Ray MicrotomographyMetabolic Reprogramming

Stichwörter der Autor:innen

Bone metabolismEGFRSOX9SRY-box transcription factor 9epidermal growth factor receptorfracture healinggefitinib

Substanzen

GefitinibSOX9 Transcription FactorErbB ReceptorsSox9 protein, rat

Autor:innen und Institutionen

  • Department of Orthopedics, The Eighth People's Hospital, Jiangsu University, Shanghai, P.R. China.
  • Department of Orthopedics, Xuhui Branch of The Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, P.R. China.
  • Department of Orthopedics, Hubei Provincial Hospital of Integrated Chinese & Western Medicine, Wuhan, P.R. China.
  • College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan, P.R. China.
  • Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.
  • Department of Orthopedics, General Hospital of Central Theater Command, Wuhan, P.R. China.

Zitieren

APA

Xu, N., Yuan, G., Zeng, W., Liu, X., Wan, M. A., Xu, S., Bi, Y., Hu, H., Xu, Y., & Lan, S. (2025). Gefitinib Facilitates Bone Fracture Healing via Inhibition of the EGFR Pathway and Counteracting SOX9-driven Bone Metabolic Reprogramming. In Vivo. https://doi.org/10.21873/invivo.13942

Vancouver

Xu N, Yuan G, Zeng W, Liu X, Wan MA, Xu S, et al. Gefitinib Facilitates Bone Fracture Healing via Inhibition of the EGFR Pathway and Counteracting SOX9-driven Bone Metabolic Reprogramming. In Vivo. 2025. doi:10.21873/invivo.13942

BibTeX
@article{Xu2025,
  author = {Xu, Ning and Yuan, Gongwu and Zeng, Wenbo and Liu, Ximing and Wan, M A and Xu, Suyang and Bi, Yikang and Hu, Hai and Xu, Yafeng and Lan, Shenghui},
  title = {Gefitinib Facilitates Bone Fracture Healing via Inhibition of the EGFR Pathway and Counteracting SOX9-driven Bone Metabolic Reprogramming},
  journal = {In Vivo},
  year = {2025},
  doi = {10.21873/invivo.13942}
}
Kostenlos starten →